Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox(Emory University), Peter Sklar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adriano Lazzarin(Vita-Salute San Raffaele University), Xia Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jing Zhao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark J. DiNubile(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard B. Pollard(University of California, Davis), Angela Williams‐Diaz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel S Berger(University of Illinois Chicago), Edwin DeJesus(Orlando Immunology Center), Richard J. O. Barnard(Merck & Co., Inc., Rahway, NJ, USA (United States)), José Valdez Madruga, Michael D. Miller(United States Military Academy), Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bach-Yen Nguyen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anthony Rodgers(New South Wales Department of Health)
Cited by 620
Related Papers
Genome sequencing in microfabricated high-density picolitre reactors
|Nature|2005|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Selected major risk factors and global and regional burden of disease
|The Lancet|2002|3.6k